The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment

doi:10.1038/s41598-021-92753-4

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/34403

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34403

Title:	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
Authors:	Fang, Jing-Hung Chen, Yi-Chen Ho, Chung-Han Chen, Jui-Yi Hsing, Chung-Hsi Liang, Fu-Wen Wu, Chia-Chun
Contributors:	Chi Mei Med Ctr, Dept Nephrol Chi Mei Med Ctr, Dept Med Res Chi Mei Med Ctr, Dept Anaesthesiol Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth Kaohsiung Med Univ Hosp, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Pharm
Keywords:	RETROSPECTIVE-COHORT ASPIRIN HEMORRHAGE WOMEN SCORE MEN
Date:	2021
Issue Date:	2023-11-11 11:49:58 (UTC+8)
Publisher:	NATURE RESEARCH
Abstract:	Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis. This study aimed to evaluate the bleeding risk with CKD patients undergoing pentoxifylline (PTX) treatment with/without aspirin. In this retrospective study, we used Taiwan's National Health Insurance Research Database to identify PTX treated CKD patients. Patients undergoing PTX treatment after CKD diagnosis were PTX group. A 1:4 age, sex and aspirin used condition matched CKD patients non-using PTX were identified as controls. The outcome was major bleeding event (MBE: intracranial haemorrhage (ICH) and gastrointestinal tract bleeding) during 2-year follow-up period. Risk factors were estimated using Cox regression for overall and stratified analysis. The PTX group had higher MBE risk than controls (hazard ratio (HR) 1.19; 95% confidence interval (CI) 0.94-1.50). In stratified analysis, hyperlipidaemia was a significant risk factor (HR: 1.42; 95% CI 1.01-2.01) of MBE. A daily PTX dose larger than 800 mg, females, non-regular aspirin usage, and ischaemic stroke were risk factors for MBE in PTX group. When prescribing PTX in CKD patients, bleeding should be closely monitored, especially in those with daily dose more than 800 mg, aspirin users, and with a history of ischaemic stroke.
Relation:	SCI REP-UK, v.11, n.1
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	230	View/Open
s41598-021-92753-4.pdf		1073Kb	Adobe PDF	95	View/Open

Loading...